In this research, we utilized a recently developed blocker-mediated asymmetric PCR assay (22) designed to investigate the frequency and subtype-specific prognostic implications of PIK3CA mutations (H1047R and E545K) in plasma-derived cell-free DNA (cfDNA) from BC patients. The gene discussed is PIK3CA; the disease is breast cancer.